Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Oncology Exam 4 > Exam 4 > Flashcards

Exam 4 Flashcards

1
Q

List 7 learning objectives for Hematopoietic Stem Cell Transplantation (7)

A
  1. Describe purposes of stem cell transplant
  2. Understand myeloablative vs. nonmyeloablative
  3. characteristics of chemo in conditioning
  4. explain role of immunosuppressants
  5. describe appropriate monitoring plan for patient on immunosuppressants
  6. describe the supportive care measures used in stem cell transplant patients
  7. create a treatment plan for a patient with acute graft versus host disease
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

List 1 granulocyte colony stimulating factor (G-CSF) and three (3) side effects

A

Filgrastim (1) bone pain (2) n/v (3) infusion-related

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

List 1 granulocyte-macrophage colony stimulating factor (GM-CSF) and seven (7) side effects

A

Sargramostim (1) n/v (2) diarrhea (3) fever (4) skin reaction (5) infusion-related reaction (6) hypertension (7) edema

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

List 1 CXCR4 chemokine inhibitor and 3 (3) side effects

A

Plerixafor (1) nausea (2) diarrhea (3) injection site reaction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

List three (3) components of conditioning regimens

A

(1) chemotherapy; myeloablative or non (2) total body irradiation (3) immunosuppressants

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

List six (6) chemodrugs used in conditioning regimens

A

(1) busulfan (2) melphalan (3) thiotepa (4) carmustine (5) cyclophosphamide (6) cytarabine (7) etoposide (8) fludarabine (9)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

List four (4) drug interactions and three (3) dose-limiting toxicites with Busulfan

A

DI through glutathione competition (a) acetaminophen (b) metronidazole (c) azole antifungals (d) phenytoin
TOX (1) mucositis (2) hepatotoxicity (3) seizures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How to manage busulfan hepatotoxicity?

A
  1. veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS)
  2. prophylax with ursodiol 300 mg PO q8hr
  3. PK monitoring
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How to manage busulfan seizure toxicity?

A
  1. seizure prophylaxis with (a) phenytoin (b) benzodiazepines (c) levetiracetam
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

List drug interactions and dose-limiting toxicity with melphalan?

A

DI: none
TOX: mucositis, manage w/ 60-min cryotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

List drug interactions and two (2) dose-limiting toxicity with thiotepa?

A

DI: CYP2B6 inhibitor, give cyclophosphamide first.
TOX: mucositis, neurotoxicity (supportive care only)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

List 1 drug interaction of carmustine and three (3) dose-limiting toxicity

A

DI: alcohol diluent so avoid dilsulfiram-drugs
TOX: hepatotoxicity, pulmonary toxicity (predisone 1 mg/kg/day), alcohol intoxication.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

List three (3) drug interaction of cyclophosphamide and three (3) dose-limiting toxicity

A

DI: (a) CYP2B6 (b) 2C9 (c) 3A4
TOX: (1) hemorrhagic cystitis (2) cardiotoxicity (3) hepatotoxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

List drug interactions with cytarabine and dose-limiting toxicity

A

DI: None
TOX: (1) neurotoxicity, uncommon at low dose.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

List two (2) drug interactions with etoposide and two dose-limiting toxicities

A

DI: (1) CYP3A4 inducers (2) CYP3A4 inhibitors
TOX: (1) mucositis (2) hypotension during infusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

List drug interaction with fludarabine and dose-limiting toxicity

A

DI: none
TOX: neurotoxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

List five (5) immunosuppressants used in bone marrow transplant

A
  1. methotrexate
  2. tacrolimus
  3. cyclosporine
  4. mycophenolate mofetil
  5. sirolimus
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

List three (3) side effects of methotrexate

A
  1. mucositis
  2. myelosuppression
  3. does NOT require alkalinization or leucovorin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

List 1 DI and four TOX of tacrolimus

A

DI: CYP3A4 inhibitors or inducers (azole antifungals reduce dose by 50%)
tox: (1) hyperkalemia, hypomagnesemia (2) tremor (3) headache (4) renal dysfunction

20
Q

List 1 DI and five TOX of cyclosporine

A

DI: CYP3A4 inhibitors or inducers
TOX: (1) hypertension (2) gingival hyperplasia (3) liver dysfunction (4) renal dysfunction (5) neurotoxicity

21
Q

List 1 DI and 3 TOX of mycophenolate

A

DI: none
TOX: (1) myelosuppressive (2) nausea (3) diarrhea

22
Q

List 1 DI and four TOX of sirolimus

A

DI: none
TOX: (1) GI upset (2) arthralgia (3) headache (4) renal dysfunction

23
Q

List three (3) immunosuppressants with TDM and their goal trough levels

A
  1. cyclosproine (150-350 nanogram/mL)
  2. tacrolimus (5-15 ng/mL)
  3. sirolimus (3-18 ng/mL)
24
Q

List four prevention medications and their purpose

A
  1. Cipro or Zosyn or cefepime (prevention of bacterial infection)
  2. Voriconazole or Fluconazole (prevention of fungal infections)
  3. Acyclovir or valacyclovir (prevention of HSV infections)
  4. Bactrim DS (prevention of PCP infections)
25
Q

List three (3) agents used in induction therapy

A
  1. Antithymocyte globulin
  2. Basiliximab
  3. Alemtuzumab
26
Q

List two (2) calcineurin inhibitors

A
  1. cyclosporine

2. tacrolimus

27
Q

List two (2) antiproliferatives

A
  1. azathioprine

2. mycophenolate

28
Q

List two (2) m-TOR inhibitors

A
  1. sirolimus

2. everolimus

29
Q

List two (2) other immunosuppressants used in solid organ transplant

A
  1. corticosteroids

2. belatacept

30
Q

List 3 aspects of thymoglobulin induction management

A
  1. premedicate with acetaminophen/diphenhydramine for infusion-related reaction
  2. monitor leukopenia and thrombocytopenia and dose adjust
  3. CMV infection possible
31
Q

List 3 aspects of basiliximab management

A
  1. MOA: IL-2 receptor antagonist
  2. monitor CBC
  3. very well tolerated, pain at site of administration
  4. no reported DDIs
32
Q

List 4 aspects of alemtuzumab management

A
  1. MOA: recombinant DNA-derived monoclonal antibody that binds to CD52
  2. rapid and extensive lymphocyte depletion
  3. premedication with acetaminophen/diphenhydramine for infusion
  4. high incidence of adverse events
33
Q

List 5 aspects of cyclosporine management

A
  1. brand names not AB rated (non-modified requiers food, variable absorption; modified has consistent exposure)
  2. MOA: binds to cyclophilin which inhibits calcineurin phosphatases, reducing t-cell activation
  3. goal trough 50-400 ng/mL
  4. metabolized by CYP3A4 and p-Gp inhibitor
  5. monitor drug levels, CBC, electrolytes, BP, LFTs, pregnancy
34
Q

List 5 aspects of tacrolimus management

A
  1. Brand names (prograf 2 divided doses, advagraf 1 daily)
  2. MOA: binds to FK-binding protein which inhibits calcineurin phosphatases
  3. goal trough 5-15 ng/mL
  4. avoid IV if possible because contains castor oil w/ anaphylaxis and nephrotox risk
  5. CYP3A4 substrate
  6. monitor drug levels, CBC, electrolytes, BP, LFTs, pregnancy
35
Q

List most common dose-limiting tox for tacrolimus and cyclosporin

A

TAC: alopecia, diabetes, hand tremor, dysesthesias, headache, insomnia
CSA: HTN, hyperlipidemia, gingival hyperplasia, hirsutism

36
Q

List five (5) aspects of azathioprine management

A
  1. MOA: prodrug for 6-mercaptopurine which is antimetabolite
  2. dose reduction in renal failure
  3. monitor for signs of myelosuppression, CBC, BBW for lymphoma, pregnancy cat D.
  4. leukopenia, thrombocyteopenia, hepatotoxicity
  5. drug interactions: allopurinol & febuxostat; 6-mercaptopurine (avoid or dose decrease; ACE inhibitor (anemia and leukopenia); warfarin (increase warfarin dose)
37
Q

List four (4) aspects of mycophenolic acid management

A
  1. MOA: reversible inhibitor of inosine monophosphatate dehydrogenase, antiproliferative
  2. monitoring: CBC, especially WBC (reduce if WBC<4), pregnancy cat D, no routine TDM.
  3. side effects: (1) diarrhea (2) n/v (3) neutropenia (4) anemia (5) hypertension
  4. interactions: (1) aluminum and Mg containing antacids (separate by 2 hr before and after); PPI (cellcept > myfortic); cholesytramine decreases absorption (separate by 2 hours before and after)
38
Q

List four (4) aspects of sirolimus management

A
  1. MOA: mTOR inhibitor, prevents progression from G1 to S phase)
  2. can substitute for CNI or substitute for azathioprine/MPA derivative
  3. metabolism: CYP3A4, PgP, half-life 62 hours
  4. monitoring: hepatic function (dose adjust by decrease 1/3 in dysfunction), lipid panel, electrolytes, urinalysis, pregnancy cat C.
  5. side effects: delayed wound healing (do not give within 30-90 days of surgery), leukopenia, thrombocytopenia, hyperlipidemia
39
Q

List four (4) aspects of everolimus management

A
  1. MOA: mTOR inhibitor
  2. trough concentration 3-8 ng/mL
  3. same ADR as sirolimus
  4. monitor CBC, complete liver panel, lipid panel, blood glucose, pregnancy cat C.
40
Q

List five (5) aspects of belatacept management

A
  1. MOA: inhibit signal 2 by antagonizing CD80 and CD86 on antigen presenting cells
  2. first long term IV maintenance immunosuppressive based on ABW
  3. contraindicated in EBV seronegative patients (increased risk of lymphoproliferative disorder)
  4. monitor prengancy cat C, serum creatinine, EBV status
  5. potential option for stable transplant patients in steroid-sparing or CNI-sparing regimens
  6. side effects fever, neutropenia, leukopenia, GI, cough, infection
41
Q

List three categories of complications in post-solid organ transplant

A
  1. malignancy (PTLD)
  2. infection (BK virus, CMV, PCJ)
  3. Chronic disease (osteoporosis, hypertension, hyperlipidemia, diabetes)
42
Q

How to manage BK virus in PSOT?

A

1st line: decrease immunosuppression

2nd line: leflunomide vs cidofavir

43
Q

How to manage CMV in PSOT?

A
  1. Low risk: no prophylaxis.
  2. Intermediate risk: valgancyclovir 450-900 mg x3 months.
  3. high risk: valganciclovir 450-900 mg po QD x 6 months
44
Q

How to manage PCJ in PSOT?

A
  1. Prophylaxis x 6 months with Bactrim, Dapsone, pentamidine or Atovaquone
45
Q

Three (3) aspects of hypertension management in PSOT

A
  1. short-acting agents (clonidine, labetalol, hydralazine) to avoid hypotension
  2. ACE/ARB - additive hyperkalemia with CNIs, increased SCr, decreasesd GFR
  3. Nondihydropyridine CCBs - inhibit CYP450 resulting in elevated CNI levels
46
Q

Two (2) aspects of hyperlipidemia in PSOT

A
  1. Statin recommended for adult kidney tx patients
  2. Statin-cyclosporine drug interactions (avoid simvastatin, lovastatin, atorvastatin, pitavastatin), USE 20 mg pravastatin, 20 mg fluvastatin, 5 mg rosuvastatin.

Oncology Exam 4 (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions